Abstract

The potential for active pharmaceutical intermediates and active ingredients to contain low levels of N-nitrosamines is a topic of continued interest from industry and regulatory authorities, which has led us to generate experimental data demonstrating that the published kinetic model of dialkylamine nitrosation is conservative and may overpredict the level of N-nitrosamine formation that will actually occur. Additionally, studies comparing the nitrosation of simple trialkylamines to that of the relevant dialkylamines have demonstrated that trialkylamines do indeed undergo nitrosative dealkylation to form N-nitrosamines but at a rate that is at least 500 times lower than for the related dialkylamines.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call